All In Biotech

Drug Trial Radar · NCT07138547

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma: an Open-Label, Randomized, Phase I/II Study

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 26, 2025

Primary completion

Aug 31, 2028

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Targeted therapy against the CD30 molecule has achieved some progress in CD30-positive Hodgkin lymphoma, but its efficacy remains unsatisfactory. Previous studies have demonstrated that N-glycan modifications in the extracellular domain of target proteins can disrupt immune synapse formation with CAR-T cells. Our preliminary research has shown that ablation of N-glycans on CD30 enhances the anti-tumor effect of CD30-targeted therapy.It is hypothesized that Eliglustat, by inhibiting GSL synthesis,may potentiate the anti-tumor effect. Consequently,we designed and initiated a single-center, open-label phase I/II clinical study to evaluate the efficacy and feasibility of Eliglustat combined with CD30 targeted immunotherapy in patients with CD30-positive lymphoma. The primary endpoint of this study is the safety and efficacy of Eliglustat combined with CD30 targeted therapies.

Conditions

  • Lymphoma

Interventions

  • Eliglustat, CD30 target immunotherapyDrug

    Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week. CD30 target immunotherapy:Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with treatment-related adverse events (AEs)Time frame: Up to 120 days after the last dose of study drugs]
  2. CR rate (CRR) in the CAR-T cell plus Eliglustat treatment groupTime frame: 12 months
  3. Progression-free survival (PFS) in the BV plus Eliglustat treatment group.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.